Kenneth Wing Merrell

Kenneth Wing Merrell

Auto-generated profile, based on publicly available information

Kenneth Wing Merrell

Department of Radiation Oncology, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Advances in Radiation Oncology
Verified
Journal Article
Open access
DRDavid M. Routman
David M. Routman
AGAurelie Garant
Aurelie Garant
SLScott C. Lester
Scott C. Lester
CDCourtney N. Day
Courtney N. Day
WHWilliam S. Harmsen
William S. Harmsen
KMKenneth W. Merrell
Kenneth W. Merrell
Grade 4 lymphopenia (G4L) during radiation therapy (RT) is associated with higher rates of distant metastasis and decreased overall survival in a number of malignancies, including esophageal cancer (EC). Through a reduction in integral radiation dose, proton RT (PRT) may reduce G4L relative to photon RT (XRT). The purpose of this study was to compare G4L in patients with EC undergoing PRT versus XRT. Patients receiving curative-intent RT and concurrent chemotherapy for EC were identified. Lymphocyte nadir was defined as the lowest lymphocyte count during RT. G4L was defined as absolute lymphocyte count <200/mm3. Univariate and multivariable logistic regression analyses (MVA) were performed to assess patient and treatment factors associated with lymphopenia. A propensity-matched (PM) cohort was created using logistic regression, including baseline covariates. A total of 144 patients met the inclusion criteria. The median age was 66 years (range, 32-85 years). Of these patients, 79 received XRT (27% 3-dimensional chemo-RT and 73% intensity modulated RT) and 65 received PRT (100% pencil-beam scanning). Chemotherapy consisted of weekly carboplatin and paclitaxel (99%). There were no significant differences in baseline characteristics between the groups, except for age (median 4 years older in the PRT cohort). G4L was significantly higher in patients who received XRT versus those who received PRT (56% vs 22%; P < .01). On MVA, XRT (odds ratio [OR]: 5.13; 95% confidence interval [CI], 2.35-11.18; P < .001) and stage III/IV (OR: 4.54; 95% CI, 1.87-11.00; P < .001) were associated with G4L. PM resulted in 50 PRT and 50 XRT patients. In the PM cohort, G4L occurred in 60% of patients who received XRT versus 24% of patients who received PRT. On MVA, XRT (OR: 5.28; 95% CI, 2.14-12.99; P < .001) and stage III/IV (OR: 3.77; 95% CI, 1.26-11.30; P = .02) were associated with G4L. XRT was associated with a significantly higher risk of G4L in comparison with PRT. Further work is needed to evaluate a potential association between RT modality and antitumor immunity as well as long-term outcomes.

27 January 2022 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
RKRoman O. Kowalchuk
Roman O. Kowalchuk
BJBenjamin A. Johnson-Tesch
Benjamin A. Johnson-Tesch
JMJoseph T. Marion
Joseph T. Marion
TMTrey C. Mullikin
Trey C. Mullikin
WHWilliam S. Harmsen
William S. Harmsen
KMKenneth W. Merrell
Kenneth W. Merrell
Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy, is an advanced radiotherapy technique that enables the delivery of highly conformal ablative doses of therapeutic radiation. Stereotactic body radiation therapy is commonly used to manage spinal metastasis, with high rates of tumor control (80%-90%) and low rates of substantial toxic effects.1-5 With the substantial morbidity and mortality of progressive or uncontrolled spinal metastasis, spine SBRT is an effective means for palliation and supporting a patient’s quality of life.

1 November 2020 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
WBWilliam G. Breen
William G. Breen
KLKonstantinos Leventakos
Konstantinos Leventakos
HDHaidong Dong
Haidong Dong
KMKenneth W. Merrell
Kenneth W. Merrell
Immunotherapy (IO) has become a standard treatment in patients with metastatic and locally advanced non-small cell lung cancer (NSCLC), and is now being tested in patients with early stage disease. IO agents currently in use for lung cancer target PD-1, PD-L1, and CTLA-4. While survival and tumor control have improved with IO, many patients have limited or short responses to IO. Therefore, methods to improve the systemic response to IO are needed. Radiation therapy (RT) is an integral component of lung cancer treatment, and may improve systemic response to IO by increasing antigen presentation, increasing co-stimulatory signaling, increasing T-cells recruitment, upregulating PD-L1, increasing tumor stromal lymphocyte infiltration, and altering the microenvironment. IO after definitive chemoradiation is now standard treatment in unresectable stage III NSCLC following publication of the PACIFIC clinical trial. For early stage NSCLC, IO is being investigated in conjunction with stereotactic body radiotherapy (SBRT). The benefit of adding RT to IO in patients with metastatic disease may be especially pronounced in patients with low baseline PD-L1 expression, potentially when delivered as a short course of SBRT, as supported by the PEMBRO-RT clinical trial. Current and ongoing clinical trials are evaluating the optimal radiation dose, timing, and sequencing of RT with IO.

1 July 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SLScott C. Lester
Scott C. Lester
SLSteven H. Lin
Steven H. Lin
MCMichael Chuong
Michael Chuong
NBNeha Bhooshan
Neha Bhooshan
ZLZhongxing Liao
Zhongxing Liao
KMKenneth W. Merrell
Kenneth W. Merrell

4 January 2021 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
CCCarrie M. Carr
Carrie M. Carr
JBJohn C. Benson
John C. Benson
DDDavid R. DeLone
David R. DeLone
FDFelix E. Diehn
Felix E. Diehn
DKDong Kun Kim
Dong Kun Kim
DJDerek R. Johnson
Derek R. Johnson

1 April 2019 in Advances in Radiation Oncology
Verified
Journal Article
Open access
AAAndrea L.H. Arnett
Andrea L.H. Arnett
BMBenjamin Mou
Benjamin Mou
DODawn Owen
Dawn Owen
SPSean S. Park
Sean S. Park
KNKaty Nelson
Katy Nelson
KMKenneth W. Merrell
Kenneth W. Merrell
Previous studies suggest that stereotactic body radiation therapy (SBRT) is associated with higher toxicity rates for central lung tumors relative to peripheral tumors when using 3 fraction SBRT. The initial results from Radiation Therapy Oncology Group study 0813 suggest a safe toxicity profile of SBRT administered in 5 fractions for central non-small cell lung cancer (NSCLC). We reviewed our institutional data to evaluate the safety and efficacy of SBRT for central NSCLC. We reviewed our prospectively collected SBRT database for patients with central NSCLC who received SBRT between 2008 and 2014. The most frequent dose and fractionations were 50 Gy in 5 fractions (59%) and 48 Gy in 4 fraction (30%). Local control (LC), regional control, metastasis-free survival, and overall survival were calculated using Kaplan-Meier estimates. The National Cancer Institute Common Terminal Criteria for Adverse Events were used for toxicity grading. A total of 110 central lung tumors in 103 patients were included. The median age was 74 years (range, 40-95 years), and the median follow-up time of living patients was 50 months. The mean tumor size was 20 mm (range, 5-70 mm). The 5 year rate of LC, regional control, and distant control was 89%, 77%, and 82%, respectively. The median and 5-year overall survival were 3.5 years and 35%, respectively. No treatment variables were associated with tumor control or other clinical outcomes. A single patient experienced grade 3 radiation pneumonitis (0.97%). The rate of late toxicity grade ≥3 was 9.7% (grade 3, 7.7%; grade 4, 0.97%; grade 5, 0.97%) and included pneumonitis (3.9%), bronchial necrosis (2.9%), myocardial dysfunction (1.9%), and worsening heart failure (0.97%). SBRT for central NSCLC provides high rates of LC. Despite excellent LC, patients remain at risk for regional and distant failure. The rate of grade 3 pneumonitis was consistent with that of prior reports. We observed low rates of grade 4-5 toxicity potentially attributable to SBRT. Our results contribute to the growing body of data in support of the safety of SBRT for central NSCLC.